Bottom line
Survodutide is a dual glucagon/GLP-1 receptor agonist in late-stage clinical development by Boehringer Ingelheim. Unlike tirzepatide (which pairs GLP-1 with GIP), survodutide pairs GLP-1 with glucagon — a hormone traditionally associated with raising blood sugar. The counterintuitive combination produces:
- Significant weight loss — up to 18-19% total body weight loss at 46 weeks in Phase 2 trials
- Dramatic reduction in liver fat — a finding that positions it as a potential treatment for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH), one of the largest unmet needs in hepatology
- Improved metabolic markers — HbA1c, lipids, liver enzymes
Survodutide is not yet FDA-approved. Phase 3 trials for both obesity and MASH are ongoing, with potential approval timelines in 2027-2028.
The mechanism: how GLP-1 plus glucagon actually works
To understand survodutide, you need to understand what glucagon does beyond its textbook role of raising blood sugar.
The GLP-1 component works the same way as semaglutide or tirzepatide's GLP-1 activity: it enhances glucose-dependent insulin secretion, slows gastric emptying, and suppresses appetite through central nervous system signaling. This is the established mechanism behind every GLP-1 drug on the market.
The glucagon component is where survodutide diverges. Glucagon receptor activation does three things that matter for obesity and liver disease:
1. Increases energy expenditure. Glucagon activates thermogenesis (calorie burning) in brown adipose tissue and the liver. This means survodutide may increase the calories you burn at rest — a fundamentally different mechanism from GLP-1 drugs that primarily reduce the calories you consume. In practical terms, survodutide attacks the energy balance equation from both sides: less in, more out.
2. Mobilizes liver fat. Glucagon promotes hepatic lipid oxidation — the burning of fat stored in the liver. For patients with fatty liver disease (NAFLD/MASH), this is precisely the mechanism needed. GLP-1s alone reduce liver fat somewhat through weight loss. Glucagon co-agonism may reduce liver fat more directly and substantially. This is survodutide's most distinctive clinical advantage.
3. Reduces appetite. Glucagon receptor activation in the brain contributes to satiety, complementing the GLP-1 appetite suppression. The two pathways together may produce stronger appetite reduction than either alone.
The GLP-1 component offsets glucagon's blood-sugar-raising effect by enhancing glucose-dependent insulin secretion. The net glycemic effect in trials has been neutral to beneficial — meaning survodutide does not raise blood sugar despite containing a glucagon agonist.
How survodutide differs from other pipeline drugs
The incretin drug landscape is crowded. Here is where survodutide fits relative to the drugs most often compared to it:
vs. Tirzepatide (Zepbound): Tirzepatide pairs GLP-1 with GIP (glucose-dependent insulinotropic polypeptide). GIP enhances insulin secretion and has metabolic effects, but it does not increase energy expenditure or directly mobilize liver fat the way glucagon does. Tirzepatide produces more weight loss in head-to-head comparisons so far (22.5% at 72 weeks vs. survodutide's 18.7% at 46 weeks), but the comparison is imperfect — different trial lengths, different populations. Tirzepatide has no special liver fat signal beyond what comes from weight loss.
vs. Retatrutide (Lilly): Retatrutide is a triple agonist — GLP-1, GIP, and glucagon all in one molecule. It has produced the largest weight loss numbers of any drug in the class (up to 24% at 48 weeks in Phase 2). It includes the glucagon component that survodutide has, plus the GIP component that survodutide lacks. In theory, retatrutide should outperform survodutide on weight loss. The question is whether survodutide's simpler dual mechanism produces a better tolerability profile or a more targeted liver effect. Phase 3 data for retatrutide is expected in 2026-2027.
vs. CagriSema (Novo Nordisk): CagriSema combines cagrilintide (an amylin analog) with semaglutide. It is a completely different approach — amylin works through different satiety pathways. CagriSema's Phase 3 results have been mixed, with the REDEFINE-2 trial missing its primary endpoint for diabetes patients. It does not have the liver fat advantage that survodutide offers.
Phase 2 trial results in detail
Obesity (ACHIEVE trial):
- 46 weeks of treatment in adults with obesity (BMI 30+ or 27+ with comorbidities)
- Survodutide at 4.8 mg weekly: approximately 14.9% body weight loss
- Survodutide at 6.0 mg weekly: approximately 18.7% body weight loss
- Placebo: approximately 2.1%
- The 18.7% figure at 46 weeks is notable because it approaches the weight loss seen with tirzepatide at 72 weeks in a shorter timeframe
MASH/liver disease (SYNCHRONIZE trials):
- Survodutide produced statistically significant reductions in liver fat (measured by MRI-PDFF) compared to placebo
- In the SYNCHRONIZE-1 trial, survodutide achieved MASH resolution without worsening of fibrosis in a significantly higher proportion of patients than placebo
- Meaningful improvement in MASH histology scores — the gold standard measure for liver disease clinical trials
- Reduction in liver fibrosis markers, suggesting potential to slow or reverse liver scarring
- Liver enzyme normalization (ALT, AST) in a majority of treated patients
- These liver-specific results are what make survodutide unique in the GLP-1 adjacent class — no other drug in this family has shown comparable liver effects
The MASH data is particularly important because there are very few effective pharmacotherapies for MASH. Resmetirom (Rezdiffra) was approved in 2024 for MASH with fibrosis, but it works through a different mechanism (thyroid hormone receptor). Survodutide could become a second approved option that also addresses obesity — a common comorbidity in MASH patients.
Side effect profile
- GI events (nausea, diarrhea, vomiting) were the most common adverse events, consistent with the GLP-1 class
- Rates were slightly higher than pure GLP-1 drugs, likely due to the glucagon component adding its own GI effects
- Heart rate increases were observed (a known glucagon effect), though clinically modest in the Phase 2 data. This will be closely watched in Phase 3, as any signal of cardiovascular risk would be a significant concern.
- Discontinuation rates due to adverse events were higher than semaglutide trials, suggesting tolerability may be a challenge at higher doses
- No signal of increased hypoglycemia, confirming that the GLP-1 component adequately offsets glucagon's glucose-raising effect
- Appetite suppression was reported as strong and consistent, comparable to high-dose semaglutide
Tolerability at the higher (more effective) doses is the key question for Phase 3. If a meaningful proportion of patients cannot tolerate the 6.0 mg dose, the real-world efficacy will be limited to the more modest 4.8 mg results.
Phase 3 timeline and Boehringer strategy
Boehringer Ingelheim has multiple Phase 3 programs running:
- SYNCHRONIZE Phase 3 for MASH: enrolled and dosing, with results expected in late 2026 or 2027. If positive, this would support the first regulatory filing.
- ACHIEVE Phase 3 for obesity: running in parallel, with results expected in 2027.
- Boehringer is pursuing a dual-indication strategy — seeking approval for both MASH and obesity, which would position survodutide uniquely as a drug that treats the liver and the weight simultaneously.
Expected pricing is uncertain but likely to fall in the range of current GLP-1s ($200-500/month at wholesale) if approved for obesity. The MASH indication could command a premium, particularly given the limited competition in that space. Boehringer has not announced pricing strategy.
Regulatory pathway: survodutide would likely go through standard FDA review for both indications. Breakthrough therapy designation for MASH is possible given the unmet need, which could accelerate the timeline.
Who might benefit most
Survodutide is not available today, but when it is, the patients who stand to benefit most are:
- Patients with obesity AND fatty liver disease (NAFLD/MASH). This is survodutide's clearest advantage. No approved GLP-1 specifically targets liver fat through a direct mechanism.
- Patients who want both appetite reduction and increased energy expenditure. If you are someone who responds poorly to appetite-suppression-only approaches (e.g., you do not overeat much but have a low metabolic rate), the glucagon-driven energy expenditure increase could be meaningful.
- Patients who have not responded adequately to semaglutide or tirzepatide. A different receptor profile may produce a different response, though this is speculative until post-marketing data accumulates.
For now, the approved options — semaglutide, tirzepatide, orforglipron — are the drugs to discuss with your prescriber. But if liver health is a significant part of your clinical picture, ask about emerging options and whether clinical trial participation might be appropriate. Consult a prescriber for guidance on whether survodutide trials are enrolling near you.